These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

464 related articles for article (PubMed ID: 30646864)

  • 1. Association of uPA and PAI-1 tumor levels and 4G/5G variants of PAI-1 gene with disease outcome in luminal HER2-negative node-negative breast cancer patients treated with adjuvant endocrine therapy.
    Jevrić M; Matić IZ; Krivokuća A; Đorđić Crnogorac M; Besu I; Damjanović A; Branković-Magić M; Milovanović Z; Gavrilović D; Susnjar S; Kisić Tepavčević D; Stanojković T
    BMC Cancer; 2019 Jan; 19(1):71. PubMed ID: 30646864
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PAI-1 promoter polymorphism modulates uPA-PAI complex accumulation by breast cancer cells.
    Alvarez-Millán JJ; Bocos C; Ferrín V; Lucas AR; Ruibal A; Schneider J
    Oncology; 2002; 62(3):286-90. PubMed ID: 12065877
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of microarray-based RNA expression with ELISA-based protein determination of HER2, uPA and PAI-1 in tumour tissue of patients with breast cancer and relation to outcome.
    Witzel ID; Milde-Langosch K; Wirtz RM; Roth C; Ihnen M; Mahner S; Zu Eulenburg C; Jänicke F; Müller V
    J Cancer Res Clin Oncol; 2010 Nov; 136(11):1709-18. PubMed ID: 20204407
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Plasminogen activator inhibitor-1 4G/5G polymorphism in breast cancer patients and its association with tissue PAI-1 levels and tumor severity.
    Castelló R; España F; Vázquez C; Fuster C; Almenar SM; Aznar J; Estellés A
    Thromb Res; 2006; 117(5):487-92. PubMed ID: 15907980
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer.
    Zemzoum I; Kates RE; Ross JS; Dettmar P; Dutta M; Henrichs C; Yurdseven S; Höfler H; Kiechle M; Schmitt M; Harbeck N
    J Clin Oncol; 2003 Mar; 21(6):1022-8. PubMed ID: 12637466
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PAI-1 -675 4G/5G polymorphism as a prognostic biomarker in breast cancer.
    Lei H; Hemminki K; Johansson R; Altieri A; Enquist K; Henriksson R; Lenner P; Försti A
    Breast Cancer Res Treat; 2008 May; 109(1):165-75. PubMed ID: 17616807
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.
    Jänicke F; Prechtl A; Thomssen C; Harbeck N; Meisner C; Untch M; Sweep CG; Selbmann HK; Graeff H; Schmitt M;
    J Natl Cancer Inst; 2001 Jun; 93(12):913-20. PubMed ID: 11416112
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Enhanced benefit from adjuvant chemotherapy in breast cancer patients classified high-risk according to urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitor type 1 (n = 3424).
    Harbeck N; Kates RE; Look MP; Meijer-Van Gelder ME; Klijn JG; Krüger A; Kiechle M; Jänicke F; Schmitt M; Foekens JA
    Cancer Res; 2002 Aug; 62(16):4617-22. PubMed ID: 12183417
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasminogen activator inhibitor-1 (PAI-1) gene 4G/5G promoter polymorphism is not associated with breast cancer.
    Błasiak J; Smolarz B
    Acta Biochim Pol; 2000; 47(1):191-9. PubMed ID: 10961693
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Potential clinical relevance of uPA and PAI-1 levels in node-negative, postmenopausal breast cancer patients bearing histological grade II tumors with ER/PR expression, during an early follow-up.
    Buta M; Džodić R; Đurišić I; Marković I; Vujasinović T; Markićević M; Nikolić-Vukosavljević D
    Tumour Biol; 2015 Sep; 36(10):8193-200. PubMed ID: 25994573
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic impact of the inclusion of uPA/PAI-1 for adjuvant treatment decision-making in ER+/Her2- pN0 early breast cancers.
    Viala M; Alexandre M; Thezenas S; Lamy PJ; Maran-Gonzalez A; Gutowski M; Colombo PE; Romieu G; Jacot W; Guiu S
    Breast Cancer Res Treat; 2017 Oct; 165(3):611-621. PubMed ID: 28685212
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.
    Look MP; van Putten WL; Duffy MJ; Harbeck N; Christensen IJ; Thomssen C; Kates R; Spyratos F; Fernö M; Eppenberger-Castori S; Sweep CG; Ulm K; Peyrat JP; Martin PM; Magdelenat H; Brünner N; Duggan C; Lisboa BW; Bendahl PO; Quillien V; Daver A; Ricolleau G; Meijer-van Gelder ME; Manders P; Fiets WE; Blankenstein MA; Broët P; Romain S; Daxenbichler G; Windbichler G; Cufer T; Borstnar S; Kueng W; Beex LV; Klijn JG; O'Higgins N; Eppenberger U; Jänicke F; Schmitt M; Foekens JA
    J Natl Cancer Inst; 2002 Jan; 94(2):116-28. PubMed ID: 11792750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients.
    Foekens JA; Peters HA; Look MP; Portengen H; Schmitt M; Kramer MD; Brünner N; Jänicke F; Meijer-van Gelder ME; Henzen-Logmans SC; van Putten WL; Klijn JG
    Cancer Res; 2000 Feb; 60(3):636-43. PubMed ID: 10676647
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Stromal coexpression of uPA/PAI-1 protein predicts poor disease outcome in endocrine-treated postmenopausal patients with receptor-positive early breast cancer.
    Singer CF; Filipits M; Jahn SW; Abete L; Jakesz R; Greil R; Bauernhofer T; Kwasny W; Seifert M; Fitzal F; Kastner M; Schmitt M; Moinfar F; Gnant M
    Breast; 2019 Aug; 46():101-107. PubMed ID: 31132475
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Markers of the uPA system and common prognostic factors in breast cancer.
    Minisini AM; Fabbro D; Di Loreto C; Pestrin M; Russo S; Cardellino GG; Andreetta C; Damante G; Puglisi F
    Am J Clin Pathol; 2007 Jul; 128(1):112-7. PubMed ID: 17580278
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse.
    Harbeck N; Thomssen C; Berger U; Ulm K; Kates RE; Höfler H; Jänicke F; Graeff H; Schmitt M
    Breast Cancer Res Treat; 1999 Mar; 54(2):147-57. PubMed ID: 10424405
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Her-2/neu and urokinase-type plasminogen activator and its inhibitor in breast cancer.
    Konecny G; Untch M; Arboleda J; Wilson C; Kahlert S; Boettcher B; Felber M; Beryt M; Lude S; Hepp H; Slamon D; Pegram M
    Clin Cancer Res; 2001 Aug; 7(8):2448-57. PubMed ID: 11489825
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tumor stroma is the predominant uPA-, uPAR-, PAI-1-expressing tissue in human breast cancer: prognostic impact.
    Hildenbrand R; Schaaf A; Dorn-Beineke A; Allgayer H; Sütterlin M; Marx A; Stroebel P
    Histol Histopathol; 2009 Jul; 24(7):869-77. PubMed ID: 19475533
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ten-year analysis of the prospective multicentre Chemo-N0 trial validates American Society of Clinical Oncology (ASCO)-recommended biomarkers uPA and PAI-1 for therapy decision making in node-negative breast cancer patients.
    Harbeck N; Schmitt M; Meisner C; Friedel C; Untch M; Schmidt M; Sweep CG; Lisboa BW; Lux MP; Beck T; Hasmüller S; Kiechle M; Jänicke F; Thomssen C;
    Eur J Cancer; 2013 May; 49(8):1825-35. PubMed ID: 23490655
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation of Serum Levels of Urokinase Activation Plasminogen (uPA) and Its Inhibitor (PAI-1) with Hormonal and HER-2 Status in the Early Invasive Breast Cancer.
    Pusina S
    Med Arch; 2018 Nov; 72(5):335-340. PubMed ID: 30524164
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 24.